Library

An EQ-5D-5L value set for Belgium / Nicolas Bouckaert / Brussels [Belgium] : KCE = Federaal Kenniscentrum voor de Gezondheidszorg = Centre Fédéral d'Expertise des Soins de Santé = Belgian Health Care Knowledge Centre (2021)  

An EQ-5D-5L value set for Belgium : How to value health-related quality of life? [printed text] / Nicolas Bouckaert, Author ; Sophie Gerkens , Author ; Stephan Devriese , Author ; Irina Cleemput , Author . - Brussels [Belgium] : KCE = Federaal Kenniscentrum voor de Gezondheidszorg = Centre Fédéral d'Expertise des Soins de Santé = Belgian Health Care Knowledge Centre, 2021 . - 106 p. : ill., ; A4. - (KCE Reports. Health Services Research (HSR); 342) . ISSN : D/2021/120210.273/19 : € 0,00 Languages : English (eng) Descriptors: Classification W 84.3 Health Services Research (General) Indexation 2017-12 ; Cost-Benefit Analysis ; Models, Statistical ; Quality of Life ; Quality-Adjusted Life Years ; R342 ; Surveys and Questionnaires Contents note: KEY POINTS 1 -- LIST OF FIGURES 5 -- LIST OF TABLES 6 -- LIST OF ABBREVIATIONS 7 -- SCIENTIFIC REPORT 9 -- 1 INTRODUCTION 9 -- 1 1 HEALTH-RELATED QUALITY OF LIFE 9 -- 1 2 APPLICATION OF HEALTH STATE UTILITY DATA IN CLINICAL AND ECONOMIC -- EVALUATIONS 12 -- 1 3 THE EQ-5D INSTRUMENT 13 -- 1 4 STUDY OBJECTIVE 15 -- 2 METHODS 16 -- 2 1 STUDY PROTOCOL 16 -- 2 1 1 Valuation techniques 16 -- 2 1 2 EQ-VT Software 19 -- 2 1 3 Structure of the interview 19 -- 2 1 4 Target sample 20 -- 2 1 5 Number of interviewers 20 -- 2 1 6 Training and pilot tests 21 -- 2 1 7 Quality control 21 -- 2 2 SAMPLING PROCESS 21 -- 2 2 1 Inclusion and exclusion criteria 21 -- 2 2 2 Sampling procedure 22 -- 2 3 STUDY APPROVAL AND PRIVACY PROTECTION ASPECTS 31 -- 2 4 DATA COLLECTION 32 -- 2 4 1 Initial recruitment of interviewers 32 -- 2 4 2 Recruitment of respondents 32 -- 2 4 3 Data collection time frame and recruitment of new interviewers 32 -- 3 DATA ANALYSIS 37 -- 3 1 DATA PREPARATION AND REPRESENTATIVENESS 37 -- 3 1 1 Creation modelling dataset 37 -- 3 1 2 Representativeness 38 -- 3 2 MODEL CONSTRUCTION 39 -- 3 2 1 Modelling cTTO valuation 39 -- 3 2 2 Modelling DCE valuation 41 -- 3 2 3 Hybrid model 42 -- 3 2 4 Fitting of the models 43 -- 3 3 MODEL SELECTION 43 -- 3 3 1 Logical consistency 43 -- 3 3 2 Goodness of fit 43 -- 3 3 3 Predictive accuracy 44 -- 3 3 4 Theoretical considerations 45 -- 3 4 PREFERRED MODEL AND VALUE SET 46 -- 4 RESULTS: THE BELGIAN EQ-5D-5L VALUE SET 47 -- 4 1 SAMPLE CHARACTERISTICS 47 -- 4 2 DATA CHARACTERISTICS 52 -- 4 2 1 cTTO data 52 -- 4 2 2 DCE data 59 -- 4 3 MODELLING RESULTS AND SELECTION 60 -- 4 3 1 Logical consistency 60 -- 4 3 2 Goodness of fit 60 -- 4 3 3 Predictive accuracy 62 -- 4 3 4 Theoretical considerations 63 -- 4 4 VALUE SET 68 -- 4 4 1 Summary of model selection 68 -- 4 4 2 Preferred model and value set 68 -- 4 4 3 Comparison with 3L value set and value sets of other countries 72 -- 5 DISCUSSION AND CONCLUSION 75 -- 5 1 STRENGTHS AND LIMITATIONS IN THE DEVELOPMENT OF THE NEW VALUE SET 75 -- 5 2 IMPLICATIONS OF THE NEW VALUE SET 76 -- 5 3 APPLICABILITY OF THE BELGIAN EQ-5D-5L VALUE SET 77 -- 5 4 FUTURE RESEARCH AND REFLECTIONS 78 --  APPENDICES 79 -- APPENDIX 1 LIKELIHOOD FUNCTIONS IN REGRESSION ANALYSIS 79 -- APPENDIX 2 REPRESENTATIVENESS OF THE POPULATION AT REGIONAL LEVEL 82 -- APPENDIX 3 FINAL VALUE SET 85 -- REFERENCES 100 Link for e-copy: https://kce.fgov.be/sites/default/files/atoms/files/KCE_342_EQ-5D-5L_value_set_f [...] Format of e-copy: PDF (5,7 Mb) Record link: https://kce.docressources.info/index.php?lvl=notice_display&id=4743

Cost-effectiveness in health and medicine / Marthe R. Gold / Oxford ; Melbourne ; New York : Oxford University Press - OUP (1996)

Cost-effectiveness in health and medicine [printed text] / Marthe R. Gold, Editor . - Oxford ; Melbourne ; New York : Oxford University Press - OUP, 1996 . - XXIII, 425 p. : ill. ; 24 cm. ISBN : 978-0-19-510824-8 Languages : English (eng) Descriptors: Classification W 74 Medical economics. Health care costs (General) Indexation analysis [Subheading] ; Cost-Benefit Analysis ; Decision Support Techniques ; Delivery of Health Care ; Health ; Health Care ; Health Care Costs ; Health Care Rationing ; Methods ; Neural Tube Defects ; Nutritional Sciences ; Pharmaceutical Preparations ; Preventive Medicine ; Public Policy ; Quality of Life ; Quality-Adjusted Life Years ; Research ; Resource Allocation ; United States Record link: https://kce.docressources.info/index.php?lvl=notice_display&id=267

Hold

Place a hold on this item

Copies (2)

Barcode	Call number	Media type	Location	Section	Status
10273-00546	W 74/GOL	Book	KCE	Library (10.124)	Due for return by 03/31/2016
10273-00162	W74/GOL	Book	KCE	Library (10.124)	Available

Readers who borrowed this document also borrowed:

Epidemiology	Rothman, Kenneth J.
Measuring health	McDowell, Ian
Cost-effectiveness analysis	Levin, Henry M. (1938-....)
Methods for the Economic Evaluation of Health Care Programmes	Drummond, Michael F.
BADS Directory of Procedures
Ecrire en santé publique	Leguéré, Jean-Pierre
De Belgische ziekenhuisfinanciering ontcijferd	Sermeus, Walter
Measuring health	Bowling, Ann
Health economics	Zweifel, Peter
Cost and economic evaluation of radiotherapy	Lievens, Yolande
Protocoles et échelles d'évaluation en psychiatrie et en psychologie	Bouvard, Martine

Cost Effectiveness of Drug-Eluting Stents In Belgian Practice / Mattias Neyt in Pharmacoeconomics, 27(2009)4 ([04/01/2009])  

[article] Cost Effectiveness of Drug-Eluting Stents In Belgian Practice : Healthcare Payer Perspective [printed text] / Mattias Neyt , Author ; Chris De Laet , Author ; Annemieke De Ridder, Author ; Hans Van Brabandt , Author . - 2009 . - 313-27. Languages : English (eng) in Pharmacoeconomics > 27(2009)4 [04/01/2009] . - 313-27 Descriptors: Classification W 1 Serials. Periodicals Indexation 2006-08 ; Belgium ; Cost-Benefit Analysis ; Decision Support Techniques ; Drug-Eluting Stents ; Health Care Costs ; Humans ; Insurance, Health, Reimbursement ; Journal Article ; Models, Statistical ; Peer Review ; Quality-Adjusted Life Years ; R66 ; Stents Abstract: BACKGROUND: There has been a steep increase in the number of percutaneous coronary intervention procedures performed for coronary heart disease since their introduction about 30 years ago. Recently, the use of drug-eluting stents (DES) compared with the original bare metal stents (BMS) has increased in many countries. OBJECTIVE: To assess the cost effectiveness of DES versus BMS in a real-world setting from the Belgian healthcare payer perspective. METHODS: We developed a decision analysis model to estimate incremental costs (year 2004 or 2007 values [depending on the underlying variable]) and effectiveness. Incremental effectiveness was calculated by combining relative benefits from published meta-analyses with real-world observations from a Belgian registry. Probabilistic modelling and sensitivity analyses were performed. The model had a 1-year time horizon. Sixteen sub groups were created based on the following characteristics: initial stent type, diabetic status, complex lesion and multi-vessel disease. Scenario analyses were performed for the influence on reinterventions and the duration of clopidogrel use. In each analysis, 1000 Monte Carlo simulations were performed. RESULTS: The incremental costs for switching from BMS to DES are substantial (approximately euro1000), while the benefits, expressed as QALYs, are extremely small (on average <0.001 QALYs gained). This led to very high incremental cost-effectiveness ratios: over euro860 000 per QALY gained in all subgroups and scenario analyses. CONCLUSION: Comparing DES with BMS, no life-years are gained and small quality-of-life improvements are achieved for short periods, resulting in a high likelihood that DES are not cost effective. When there is competition for scarce resources this should be considered when deciding on the reimbursement of this technology. Link for e-copy: https://doi.org/10.2165/00019053-200927040-00004 Format of e-copy: PDF [Requires Subscription] Record link: https://kce.docressources.info/index.php?lvl=notice_display&id=2438 [article]

Cost-effectiveness of human papillomavirus vaccination in Belgium / Nancy Thiry in International Journal of Technology Assessment in Health Care, 25(2009)2 ([04/01/2009])  

[article] Cost-effectiveness of human papillomavirus vaccination in Belgium : do not forget about cervical cancer screening [printed text] / Nancy Thiry, Author ; Chris De Laet , Author ; Frank Hulstaert, Author ; Mattias Neyt , Author ; Huybrechts, Michel, Author ; Irina Cleemput , Author . - 2009 . - 161-170. Languages : English (eng) in International Journal of Technology Assessment in Health Care > 25(2009)2 [04/01/2009] . - 161-170 Descriptors: Classification W 1 Serials. Periodicals Indexation 2007-13 ; Adolescent ; Adult ; Belgium ; Child ; Cohort Studies ; Cost-Benefit Analysis ; Female ; Great Britain ; Health Care Costs ; Humans ; Journal Article ; Markov Chains ; Mass Screening ; Papillomavirus Vaccines ; Peer Review ; Quality-Adjusted Life Years ; R64 ; Uterine Cervical Neoplasms ; Vaccination Abstract: OBJECTIVES: The cost-effectiveness of adding a human papillomavirus (HPV) vaccination program in 12-year-old females to the recommended cervical cancer screening in Belgium is examined. Moreover, the health and economic consequences of a potential decline in screening uptake after initiation of a HPV vaccination program are investigated. METHODS: A static Markov model is developed to estimate the direct effect of vaccination on precancerous lesions and cervical cancers. RESULTS: Vaccination is estimated to avoid 20 percent of the cervical cancers occurring in a 12-year-old girls' cohort and to cost 32,665 euro per quality-adjusted life-year (QALY) gained (95 percent credibility interval [CrI]: 17,447 euro to 68,078 euro), assuming a booster injection after 10 years, a limited duration of protection and discounting costs and effects at 3 percent and 1.5 percent, respectively. Assuming lifelong protection, HPV vaccination is estimated to cost 14,382 euro (95 percent CrI: 9,238 euro to 25,644 euro) per QALY gained, while avoiding 50 percent of the cervical cancer cases. In the base-case, a 10 percent reduction in screening compliance after vaccination obliterates the effect of vaccination on cervical cancer cases avoided, whereas further declines in the level of screening compliance even turned out to be detrimental for the cohort's health, inducing a mean loss in QALYs and life-year gained compared with the situation prevaccination. CONCLUSIONS: An HPV vaccination program should only be considered if the level of screening after vaccination can be maintained. Link for e-copy: http://doi.org/10.1017/S0266462309090217 Format of e-copy: PDF [Requires Subscription] Record link: https://kce.docressources.info/index.php?lvl=notice_display&id=2200 [article]

Cost Effectiveness of Implantable Cardioverter-Defibrillators for Primary Prevention in a Belgian Context / Mattias Neyt in Applied Health Economics and Health Policy, 6(2008)1 ([10/01/2008])  

[article] Cost Effectiveness of Implantable Cardioverter-Defibrillators for Primary Prevention in a Belgian Context [printed text] / Mattias Neyt , Author ; Nancy Thiry, Author ; Dirk Ramaekers, Author ; Hans Van Brabandt , Author . - 2008 . - 67-80. Languages : English (eng) in Applied Health Economics and Health Policy > 6(2008)1 [10/01/2008] . - 67-80 Descriptors: Classification W 1 Serials. Periodicals Indexation 2006-07 ; Aged ; Australia ; Belgium ; Cost-Benefit Analysis ; Death, Sudden, Cardiac ; Defibrillators, Implantable ; Female ; Humans ; Journal Article ; Male ; Markov Chains ; Middle Aged ; Peer Review ; Primary Prevention ; Quality-Adjusted Life Years ; R58 Abstract: Background: Implantable cardioverter-defibrillator (ICD) therapy was traditionally applied in patients who survived a cardiac arrest or who experienced a symptomatic ventricular tachyarrhythmia. Its use in primary prevention (i.e. in patients who have yet to experience a serious arrhythmic event, but who are considered at high risk for sudden cardiac death) has become more common, and policy makers question whether ICD therapy should be reimbursed in these instances. Objective: To assess the cost effectiveness of primary prevention ICD therapy versus conventional therapy from the perspective of the Belgian health insurance system. Method: A lifetime 1-month cycle Markov model was constructed and populated with clinical and effectiveness data from the SCD-HeFT study and real-world Belgian cost data expressed in year 2005 values. Probabilistic modelling and sensitivity analyses were performed. Results: ICD therapy results in 1.22 life-years gained (LYG) or 1.03 QALYs gained. The lifetime cost-effectiveness and cost-utility ratios were €59 989 (95% CI 35 873, 113 518) per LYG and €71 428 (95% CI 40 225, 134 623) per QALY gained, respectively. A cost-effectiveness ratio <€50 000 per QALY gained was obtained in 15.5% of 1000 simulations. Increasing the service life of the device from 5 to 7 years would improve the cost effectiveness to €57 229 (95% CI 32 568, 106 410) per QALY gained. Conclusions: ICD therapy may not be judged cost effective for the primary prevention of death in patients with a SCD-HeFT profile in the Belgian context using current technology and patient selection. A combination of price reductions and increased service life of the device may alter this conclusion. Link for e-copy: http://doi.org/10.2165/00148365-200806010-00006 Format of e-copy: PDF Record link: https://kce.docressources.info/index.php?lvl=notice_display&id=2335 [article]

Drempelwaarden voor kosteneffectiviteit in de gezondheidszorg / Irina Cleemput ; Mattias Neyt ; Nancy Thiry ; Chris De Laet ; Mark Leys / Brussels [Belgium] : KCE = Federaal Kenniscentrum voor de Gezondheidszorg = Centre Fédéral d'Expertise des Soins de Santé = Belgian Health Care Knowledge Centre (2008)  

Permalink

Drempelwaarden voor kosteneffectiviteit in de gezondheidszorg / KCE = Federaal Kenniscentrum voor de Gezondheidszorg = Centre fédéral d'expertise des soins de santé / Brussels [Belgium] : KCE = Federaal Kenniscentrum voor de Gezondheidszorg = Centre Fédéral d'Expertise des Soins de Santé = Belgian Health Care Knowledge Centre (2009)

Permalink

Economic implications of non-compliance in health care / Irina Cleemput in Lancet (The), 359(2002)9324 ([06/01/2002])  

Permalink

Een Belgische waardenset voor de EQ-5D-5L / Nicolas Bouckaert / Brussels [Belgium] : KCE = Federaal Kenniscentrum voor de Gezondheidszorg = Centre Fédéral d'Expertise des Soins de Santé = Belgian Health Care Knowledge Centre (2021)  

Permalink

ICER 2009 Exposé / KCE = Federaal Kenniscentrum voor de Gezondheidszorg = Centre fédéral d'expertise des soins de santé / Brussels [Belgium] : KCE = Federaal Kenniscentrum voor de Gezondheidszorg = Centre Fédéral d'Expertise des Soins de Santé = Belgian Health Care Knowledge Centre (2009)

Permalink

ICER 2009 Panel / KCE = Federaal Kenniscentrum voor de Gezondheidszorg = Centre fédéral d'expertise des soins de santé / Brussels [Belgium] : KCE = Federaal Kenniscentrum voor de Gezondheidszorg = Centre Fédéral d'Expertise des Soins de Santé = Belgian Health Care Knowledge Centre (2009)

Permalink

Une matrice de valorisation belge pour l’EQ-5D-5L / Nicolas Bouckaert / Brussels [Belgium] : KCE = Federaal Kenniscentrum voor de Gezondheidszorg = Centre Fédéral d'Expertise des Soins de Santé = Belgian Health Care Knowledge Centre (2021)  

Permalink

ScHARRHUD / Information Resources Group (IRG) at ScHARR / Sheffield [United-Kingdom] : School of Health and Related Research (ScHARR) (2019)  

Permalink

Threshold values for cost-effectiveness in health care / Irina Cleemput ; Mattias Neyt ; Nancy Thiry ; Chris De Laet ; Mark Leys / Brussels [Belgium] : KCE = Federaal Kenniscentrum voor de Gezondheidszorg = Centre Fédéral d'Expertise des Soins de Santé = Belgian Health Care Knowledge Centre (2008)  

Permalink

Trastuzumab in early stage breast cancer / Mattias Neyt in Health Policy, 82(2008)2 ([08/01/2008])  

Permalink